Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(Suppl 1):31–37. doi: 10.1054/bjoc.2001.1750

Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy

G D Demetri 1
PMCID: PMC2363900  PMID: 11308272

Abstract

Anaemia is a common occurrence in patients with cancer and contributes to the clinical symptomatology and reduced quality of life (QOL) seen in cancer patients. Many aspects of reduced QOL, including fatigue, are known to be associated with suboptimally low levels of haemoglobin. Even mild-to-moderate anaemia adversely affects patient-reported QOL parameters. Red blood cell transfusions are associated with many real and perceived risks, inconveniences, costs, and only temporary benefits. Recombinant human erythropoietin (rHuEPO) is an effective therapy to increase haemoglobin values in over half of anaemic cancer patients receiving concurrent chemotherapy. These increased haemoglobin values are closely correlated with improvements in QOL. Despite these objectively defined benefits, less than 50% of anaemic patients undergoing cytotoxic chemotherapy receive rHuEPO, in contrast to patients with chronic renal failure on dialysis, where anaemia is universally and aggressively treated to more optimal haemoglobin values. However, there are several barriers that may limit more widespread use of rHuEPO. These include inconvenience associated with frequent dosing; failure of a large proportion (40 to 50%) of patients to respond; relatively slow time to response; absence of reliable early indicators of response; and current lack of rigorous pharmacoeconomic data demonstrating cost-effectiveness. Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP) that is biochemically distinct from rHuEPO, and which has been proven to stimulate red blood cell production. The molecule has a 3-fold longer half-life and increased biological activity that will allow less frequent dosing, facilitating improved management of the anaemia of cancer. With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer. © 2001 Cance Cancer Research Campaign

Keywords: anaemia, cancer, chemotherapy, radiotherapy, recombinant human erythropoietin, darbepoetin alfa

Full Text

The Full Text of this article is available as a PDF (125.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abels R. I. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992 Jun;19(3 Suppl 8):29–35. [PubMed] [Google Scholar]
  2. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A Suppl 2:S2–S8. doi: 10.1016/s0959-8049(05)80281-3. [DOI] [PubMed] [Google Scholar]
  3. Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg. 1996;51(1):36–52. [PubMed] [Google Scholar]
  4. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol. 1998 Jun;25(3 Suppl 7):27–34. [PubMed] [Google Scholar]
  5. Cascinu S., Fedeli A., Del Ferro E., Luzi Fedeli S., Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994 May;12(5):1058–1062. doi: 10.1200/JCO.1994.12.5.1058. [DOI] [PubMed] [Google Scholar]
  6. Case D. C., Jr, Bukowski R. M., Carey R. W., Fishkin E. H., Henry D. H., Jacobson R. J., Jones S. E., Keller A. M., Kugler J. W., Nichols C. R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993 May 19;85(10):801–806. doi: 10.1093/jnci/85.10.801. [DOI] [PubMed] [Google Scholar]
  7. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997 Jul;34(3 Suppl 2):13–19. [PubMed] [Google Scholar]
  8. Crémieux P. Y., Barrett B., Anderson K., Slavin M. B. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol. 2000 Jul;18(14):2755–2761. doi: 10.1200/JCO.2000.18.14.2755. [DOI] [PubMed] [Google Scholar]
  9. Curt G. A., Breitbart W., Cella D., Groopman J. E., Horning S. J., Itri L. M., Johnson D. H., Miaskowski C., Scherr S. L., Portenoy R. K. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–360. doi: 10.1634/theoncologist.5-5-353. [DOI] [PubMed] [Google Scholar]
  10. Curt GA. The Impact of Fatigue on Patients with Cancer: Overview of FATIGUE 1 and 2. Oncologist. 2000 Jun;5 (Suppl 2):9–12. [PubMed] [Google Scholar]
  11. Demetri G. D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998 Oct;16(10):3412–3425. doi: 10.1200/JCO.1998.16.10.3412. [DOI] [PubMed] [Google Scholar]
  12. Dubray B., Mosseri V., Brunin F., Jaulerry C., Poncet P., Rodriguez J., Brugère J., Point D., Giraud P., Cosset J. M. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996 Nov;201(2):553–558. doi: 10.1148/radiology.201.2.8888257. [DOI] [PubMed] [Google Scholar]
  13. Estrin J. T., Schocket L., Kregenow R., Henry D. H. A retrospective review of blood transfusions in cancer patients with anemia. Oncologist. 1999;4(4):318–324. [PubMed] [Google Scholar]
  14. Fein D. A., Lee W. R., Hanlon A. L., Ridge J. A., Langer C. J., Curran W. J., Jr, Coia L. R. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995 Aug;13(8):2077–2083. doi: 10.1200/JCO.1995.13.8.2077. [DOI] [PubMed] [Google Scholar]
  15. Fyles A. W., Milosevic M., Wong R., Kavanagh M. C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T. J. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998 Aug;48(2):149–156. doi: 10.1016/s0167-8140(98)00044-9. [DOI] [PubMed] [Google Scholar]
  16. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997 Mar;15(3):1218–1234. doi: 10.1200/JCO.1997.15.3.1218. [DOI] [PubMed] [Google Scholar]
  17. Glaspy J., Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Williston Park) 1999 Apr;13(4):461-73; discussion 477-8, 483-8. [PubMed] [Google Scholar]
  18. Glaspy J., Jadeja J. S., Justice G., Kessler J., Richards D., Schwartzberg L., Rigas J., Kuter D., Harmon D., Prow D. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr;84 (Suppl 1):17–23. doi: 10.1054/bjoc.2001.1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Goodnough L. T., Brecher M. E., Kanter M. H., AuBuchon J. P. Transfusion medicine. First of two parts--blood transfusion. N Engl J Med. 1999 Feb 11;340(6):438–447. doi: 10.1056/NEJM199902113400606. [DOI] [PubMed] [Google Scholar]
  20. Grogan M., Thomas G. M., Melamed I., Wong F. L., Pearcey R. G., Joseph P. K., Portelance L., Crook J., Jones K. D. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999 Oct 15;86(8):1528–1536. doi: 10.1002/(sici)1097-0142(19991015)86:8<1528::aid-cncr20>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  21. Groopman J. E., Itri L. M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999 Oct 6;91(19):1616–1634. doi: 10.1093/jnci/91.19.1616. [DOI] [PubMed] [Google Scholar]
  22. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-Associated Anemia: The Scope of the Problem. Oncologist. 2000 Jun;5 (Suppl 2):1–7. [PubMed] [Google Scholar]
  23. Heatherington A. C., Schuller J., Mercer A. J. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer. 2001 Apr;84 (Suppl 1):11–16. doi: 10.1054/bjoc.2001.1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Henry D. H., Abels R. I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol. 1994 Apr;21(2 Suppl 3):21–28. [PubMed] [Google Scholar]
  25. Khayat D. Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol. 2000 Apr;27(2 Suppl 4):9–17. [PubMed] [Google Scholar]
  26. Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994 May 15;73(10):2535–2542. doi: 10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  27. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant. 1999;14 (Suppl 2):85–92. doi: 10.1093/ndt/14.suppl_2.85. [DOI] [PubMed] [Google Scholar]
  28. Ludwig H., Fritz E. Anemia in cancer patients. Semin Oncol. 1998 Jun;25(3 Suppl 7):2–6. [PubMed] [Google Scholar]
  29. Ludwig H., Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol. 1998 Jun;25(3 Suppl 7):35–38. [PubMed] [Google Scholar]
  30. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994 Aug 15;84(4):1056–1063. [PubMed] [Google Scholar]
  31. Ludwig H., Sundal E., Pecherstorfer M., Leitgeb C., Bauernhofer T., Beinhauer A., Samonigg H., Kappeler A. W., Fritz E. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995 Dec 1;76(11):2319–2329. doi: 10.1002/1097-0142(19951201)76:11<2319::aid-cncr2820761121>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  32. Macdougall I. C., Gray S. J., Elston O., Breen C., Jenkins B., Browne J., Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999 Nov;10(11):2392–2395. doi: 10.1681/ASN.V10112392. [DOI] [PubMed] [Google Scholar]
  33. Macdougall I. C. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000 Jul;20(4):375–381. [PubMed] [Google Scholar]
  34. Mercadante S., Gebbia V., Marrazzo A., Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000 Aug;26(4):303–311. doi: 10.1053/ctrv.2000.0181. [DOI] [PubMed] [Google Scholar]
  35. Ray-Coquard I., Le Cesne A., Rubio M. T., Mermet J., Maugard C., Ravaud A., Chevreau C., Sebban C., Bachelot T., Biron P. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol. 1999 Sep;17(9):2840–2846. doi: 10.1200/JCO.1999.17.9.2840. [DOI] [PubMed] [Google Scholar]
  36. Smith R. E., Jr, Jaiyesimi I. A., Meza L. A., Tchekmedyian N. S., Chan D., Griffith H., Brosman S., Bukowski R., Murdoch M., Rarick M. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001 Apr;84 (Suppl 1):24–30. doi: 10.1054/bjoc.2001.1749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Stone P., Richardson A., Ream E., Smith A. G., Kerr D. J., Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000 Aug;11(8):971–975. doi: 10.1023/a:1008318932641. [DOI] [PubMed] [Google Scholar]
  38. Vogelzang N. J., Breitbart W., Cella D., Curt G. A., Groopman J. E., Horning S. J., Itri L. M., Johnson D. H., Scherr S. L., Portenoy R. K. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997 Jul;34(3 Suppl 2):4–12. [PubMed] [Google Scholar]
  39. Warde P., O'Sullivan B., Bristow R. G., Panzarella T., Keane T. J., Gullane P. J., Witterick I. P., Payne D., Liu F. F., McLean M. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):347–353. doi: 10.1016/s0360-3016(98)00062-5. [DOI] [PubMed] [Google Scholar]
  40. Yellen S. B., Cella D. F., Webster K., Blendowski C., Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997 Feb;13(2):63–74. doi: 10.1016/s0885-3924(96)00274-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES